Insider Monkey
Corvus Pharmaceuticals (CRVS) Hits All-Time High on Eczema Trial Results
📈
AI Sentiment
Highly Positive
10/10
Corvus Pharmaceuticals Inc. News
Latest updates and market news for CRVS
12 news
Jan 17 - Jan 23, 2026
Page 1
MT Newswires
Corvus Pharmaceuticals Prices $175 Million Upsized Common Stock Offering
âž–
AI Sentiment
Neutral
4/10
GlobeNewswire
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
📊
AI Sentiment
Positive
6/10
MT Newswires
Mizuho Boosts Price Target on Corvus Pharmaceuticals to $20 From $13, Keeps Outperform Rating
📊
AI Sentiment
Positive
7/10
BioPharma Dive
Corvus shares nearly triple on positive data for eczema pill
📈
AI Sentiment
Highly Positive
10/10
Simply Wall St.
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Positive Soquelitinib Phase 1 Atopic Dermatitis Data
📈
AI Sentiment
Highly Positive
9/10
Motley Fool
Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
Corvus Pharmaceuticals Launches $150 Million Equity Offering
âž–
AI Sentiment
Neutral
4/10
Investor's Business Daily
Why Small Biotech Stock Corvus Pharma Just Launched To A Nine-Year High
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
Corvus Pharmaceuticals Says New Soquelitinib Data Show Safety, Efficacy in Atopic Dermatitis
âž–
AI Sentiment
Neutral
5/10
GlobeNewswire
Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
📈
AI Sentiment
Highly Positive
9/10
Share this news page